<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/PURPOSE: The activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2(V617F)) is associated with myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPNs), including <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET), and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report a technical advance in the diagnosis of JAK2(V617F) in MPNs by melting curve analysis (<z:chebi fb="70" ids="34342">MCA</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: From January through December 2006, we prospectively enrolled 78 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (n = 21), ET (n = 32), <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (n = 5), secondary <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> (n = 4), secondary <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (n = 2), <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (n = 4), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 8), and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 2) </plain></SENT>
<SENT sid="3" pm="."><plain>Mutation analysis for JAK2(V617F) was performed on either bone marrow or peripheral blood cells using allele-specific polymerase chain reaction (AS-PCR) or sequencing and fluorescence resonance energy transfer (FRET) probes with <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: For the initial 30 samples, the detection rate of JAK2(V617F) using <z:chebi fb="70" ids="34342">MCA</z:chebi> was comparable to the gold standard of the PCR sequencing methods </plain></SENT>
<SENT sid="5" pm="."><plain>However, the turnaround times for <z:chebi fb="70" ids="34342">MCA</z:chebi> and PCR were 2 hours and 2 days, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The detection rate of JAK2(V617F) was 76.2% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (homozygous in 14.3%), 46.9% for ET, 80% for <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (homozygous in 20%), and 0% for the other conditions </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, patients with homozygous JAK2(V617F) presented with significantly longer disease durations than heterozygous patients </plain></SENT>
<SENT sid="8" pm="."><plain>In ET, there were no differences in the clinical parameters of patients harboring JAK2(V617F) compared with those with <z:mp ids='MP_0002169'>wild-type</z:mp> JAK2 </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Heterozygous and homozygous JAK2(V617F) mutations can be identified using the rapid and reliable assay based on FRET probes and <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Detection of JAK2(V617F) can be used to assist in the diagnosis of BCR/ABL-negative MPNs </plain></SENT>
</text></document>